SHC Sotera Health

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.

To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live webcast of the conference will be accessible at this or via the Investor Relations section of the Company’s website at , along with the accompanying materials. A replay of the webcast will be available on the Company’s website later in the day on November 5th.

Investor Day

Sotera Health will hold its inaugural Investor Day on Wednesday, November 20, 2024 at 12:30 p.m. Eastern Time in New York City with presentations by members of the management team. Attendance at the in-person event is by invitation only. Parties interested in attending in person can send inquiries to .

A live webcast of the event will be accessible at . Virtual participants are encouraged to pre-register at this and log in to the webcast approximately 5-10 minutes prior to the start of the event. A live question-and-answer session will follow management’s prepared remarks. Sotera Health intends to make the investor presentation for the event available concurrently with the start of the event. A replay of the video webcast will be available within 48 hours following the conclusion of the event at .

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at . For developments related to Ethylene Oxide, updates can be found at .

Contacts

Jason Peterson

Vice President Investor Relations & Treasurer, Sotera Health

Kristin Gibbs

Chief Marketing Officer, Sotera Health

Source: Sotera Health Company



EN
22/10/2024

Underlying

SHCSotera Health

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE
Free
SHC SOTERA HEALTH

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SHC SOTERA HEALTH

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Resul...

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth r...

November 4, 2025 1 EN
 PRESS RELEASE
Free
SHC SOTERA HEALTH

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

Sotera Health Announces Third-Quarter 2025 Earnings Release Date CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and oper...

October 21, 2025 1 EN
 PRESS RELEASE
Free
SHC SOTERA HEALTH

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not...

September 3, 2025 1 EN
 PRESS RELEASE
Free
SHC SOTERA HEALTH

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Result...

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues ou...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch